ORKA

Oruka Therapeutics, Inc.
CAPPED RATING

Oruka Therapeutics, Inc. (ORKA) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -36.5
EV / EBITDA -34.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -6.5%
Price Return 12M 272.3%
Catalyst Signal 0.00
Market Cap $7.1B
TTM Revenue N/A
Price / Sales N/A
ROE -18.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) D+ (1.6) B- (2.9) B- (2.9) C+ (2.6) C+ (2.5)
2026-11-07 C+ (2.5) D (1.4) B- (2.9) B- (2.9) C+ (2.7) C (2.5)
2026-10-31 C+ (2.5) D (1.4) B- (2.9) B- (3.1) C+ (2.7) C+ (2.5)
2026-10-24 C+ (2.5) D (1.4) B- (2.9) B- (2.9) C+ (2.6) C (2.5)
2026-10-17 C+ (2.5) D (1.4) B- (2.9) B- (3.1) C+ (2.6) C+ (2.5)
Page 1 of 4